Sale

Exosomes Drug Market

Global Exosomes Drug Market Size, Share, Trends, Analysis: By Biomolecule Type: Non-Coding RNAs, mRNA (exoRNA), Proteins/Peptides , DNA Fragments, Lipids; By Product Type: Kits, Reagents, Instruments; By Application: Biomarkers, Drug Delivery System, Others; By Disease Type; Regional Analysis; Supplier Landscape; 2024-2032

Exosomes Drug Market Outlook

The rising cases of cancer have been driving the value of the global exosomes drug market. The number of cancer cases was close to 23.39 million in 2023. The prevalence of cancer diseases is likely to grow at the rate of 6.6% in the forecast period of 2024-2032. With this growth rate, the number of cases is likely to reach nearly 41.40 million by 2032.

 

Introduction

Exosomes are small membrane vesicles of endocytic origin that are released from various cells in culture and are formed by plasma membrane fusion with the intermediate intracellular compartment and multivesicular body (MVB) fusion.

 

Exosomes are nano-sized vesicles capable of carrying DNA, small RNA, non-coding RNA, and lipids, with or without direct cell-to-cell communication, representing a new method of cell-to-cell communication.

 

Exosomes play a vital role in immune responses , viral pathogenicity, pregnancy, cardiovascular disease, central nervous system disease, and cancer progression. Biomolecules, including proteins, metabolites, and nucleic acids, are delivered to target cells by exosomes to adjust biological responses.

 

Exosomes  are designed to deliver variety of therapeutic payloads, including short-interference ribonucleic acids (RNAs), antiallergic oligonucleotides, chemotherapeutic agents, and immunomodulatory agents, and direct their delivery to the desired targets. Liquid biopsy, based on exosome vesicle, can be used to diagnose and determine prognosis in patients with cancer and other diseases. Therefore, the increase in cancer cases in hospitals directly increases the demand for the drugs.

 

exosomes drug market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

According to the global exosomes drug market research report, the market can be categorised into the following segments:

 

Market Breakup by Biomolecule Type

  • Non-Coding RNAs
  • mRNA (exoRNA)
  • Proteins/ Peptides
  • DNA Fragments 
  • Lipids

 

Market Breakup by Product Type

  • Kits
  • Reagents
  • Instruments

 

Market Breakup by Application

  • Biomarkers
  • Drug Delivery System
  • Vaccine Development
  • Therapeutic Agents
  • Others

 

Market Breakup by Disease Type

  • Cancer Disease
  • Cardiovascular Disease 
  • Neurodegenerative Disease 
  • Tissue Regeneration 
  • Infectious Disease 
  • Others

 

exosomes drug market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Breakup by Region

  • North America

United States of America

Canada

  • Europe

United Kingdom

Germany

France

Italy

Others

  • Asia Pacific

China

Japan

India

ASEAN

Australia

Others

  • Latin America

Brazil

Argentina

Mexico

Others

  • Middle East and Africa

Saudi Arabia

United Arab Emirates

Nigeria

South Africa

Others

 

Market Scenario

The rapid growth of cancer disease drives the growth of the exosomes drug market. The rising demand for advanced drug therapies and potential applications of exosomes in diagnostics are expected to drive the market growth further in the coming years.

 

The market is primarily driven by the rising cases of cancer, followed by other infectious disease. Advanced exosomes technology in drug development and discovery provides valuable insights into heterogeneity and biological function, enabling us to exploit the therapeutic and diagnostic potential in cancer and infectious diseases. Therefore, the development of medical technology is driving the growth of global exosomes drug market.

 

The increasing demand for drug therapy in the pharmaceutical and biopharmaceutical fields can be attributed to the potential of exosomes technology as a diagnostic and therapeutic tool used in the treatment of various diseases, such as neurodegeneration, cardiovascular dysfunction, and cancer.

 

The potential applications of exosomes in cancer diagnostics and the development of precision medicine will increase the use of exosomes in the diagnostic and therapeutic industries, driving the growth of the market.

 

The rising application of these drugs due to its multifunctional properties has propelled its application in the treatment of various diseases like Alzheimer's disease, chronic heart failure, Parkinson's disease, liver cancer, breast cancer, lung cancer, and prostate cancer.

 

Regional Outlook for Global Exosomes Drug Market 

North America accounted for a significant share of the global market and is expected to grow rapidly during the forecast period. The leading position of the region can be attributed to factors like excellent healthcare infrastructure, effective government policies, large base of multinational corporations, and high public awareness about diagnosis and medical assistance.

 

On the other hand, the Asia Pacific region is also expected to witness significant growth in the coming years due to the higher presence of the emerging regions and their potential of growth. The regional market is likely to witness further growth due to the competitive strategies that are adopted by players to conduct research and development activities in this sector. Also, the growth of various pharmaceutical companies in this region is another factor that is fuelling the growth of exosomes drug market.

 

exosomes drug market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Therapeutic Landscape

The exosomes drug market has been growing at a rapid rate owing to its multipurpose uses. Exosomes have been a preferred approach for treatment for various disease, including Alzheimer’s disease and COVID-19, among others. Exosomes find extensive clinical applications in the treatment of various diseases as a cell-free alternative for tissue regeneration using therapeutic cargo components, bypassing immune rejection and cytotoxicity.

 

Stem cell-derived exosomes help harness the anti-inflammatory and regenerative properties of parent cells. Thus, it is possible to design outpatient treatment of respiratory viral diseases, including SARS-CoV-2.

 

According to a few research studies, exosomes have generated positive results as mediators of intercellular communication, potentially delivering the functional proteins, mRNA transcripts, and miRNAs to cells throughout the body.

 

Research on exosomes applications is advancing rapidly, but the development of exosome-based therapy, especially the production of exosome formulations, has many difficulties due to low productivity and heterogeneity. Moreover, there are several barriers to the methods of storage, optimisation, and isolation of exosome formulations.

 

Clinical Landscape

Exosomes are associated with immune responses, viral pathogenesis, pregnancy, cardiovascular disease, diseases related to the central nervous system and the development of cancer. Exosomes do not only aid the diagnosis of diseases but also have therapeutic potential for controlling many diseases.

 

ExoFlo is a new clinical drug that has not been approved by the Food and Drug Administration. It is a product of extracellular vesicles isolated from human bone marrow stem cells or stromal cells (MSCs). The drug is in phase 2 of clinical development for the treatment of COVID-19, ARDS, and viral pneumonia.

 

Progenza is developed by Regeneus and is currently in development stage II for osteoarthritis and preclinical stages for neuropathic pain. Progenza is a cellular therapy that targets pain and inflammation, used to improve the tissues where the Secretome is present, and the Mesenchymal Signaling Cells (MSCs) themselves.

 

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the global exosomes drug market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

 

  • Danaher Corporation (Beckman Coulter Inc.)
  • Hologic Inc.
  • Lonza Group AG
  • Fujifilm Holdings Corporation
  • Miltenyi Biotec GmbH
  • Qiagen N.V.
  • Thermo Fisher Scientific Inc.
  • JSR Corporation (MBL International)
  • Illumina, Inc.
  • Takara Bio Inc.
  • Malvern Instruments Ltd. (Spectris Plc Company)
  • Abcam Plc.
  • Ampersand Capital Partner (New England Peptide, Inc.)
  • Evox Therapeutics Ltd.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Biomolecule Type
  • Product Type
  • Application
  • Disease Type
  • Region
Breakup by Biomolecule Type
  • Non-Coding RNAs
  • mRNA (exoRNA)
  • Proteins/Peptides
  • DNA Fragments
  • Lipids
Breakup by Product Type
  • Kits
  • Reagents
  • Instruments
Breakup by Application
  • Biomarkers
  • Drug Delivery System
  • Vaccine Development
  • Therapeutic Agents
  • Others
Breakup by Disease Type
  • Cancer Disease
  • Neurodegenerative Diseases
  • Cardiovascular Diseases
  • Infectious Diseases
  • Tissue Regeneration
  • Others
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Drug Adoption Parameters
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Danaher Corporation (Beckman Coulter Inc.)
  • Hologic Inc.
  • Lonza Group AG
  • Fujifilm Holdings Corporation
  • Miltenyi Biotec GmbH
  • Qiagen N.V.
  • Thermo Fisher Scientific Inc.
  • JSR Corporation (MBL International)
  • Illumina, Inc.
  • Takara Bio Inc.
  • Malvern Instruments Ltd. (Spectris Plc Company)
  • Abcam Plc.
  • Ampersand Capital Partner (New England Peptide, Inc.)
  • Evox Therapeutics Ltd.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
2    Research Methodology
3    Executive Summary
4    Exosomes Drug Overview

    4.1    Drug Overview
        4.1.1    Pharmacodynamics
        4.1.2    Pharmacokinetics
        4.1.3    Adverse Events
5    Patient Profile
    5.1    Patient Profile Overview
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Treatment Success Rate
6    Global Exosomes Drug Market
    6.1    Global Exosomes Drug Market Overview
    6.2    Global Exosomes Drug Market Analysis 
        6.2.1    Market Overview
            6.2.1.1    Global Exosomes Drug Market Historical Value (2017-2023) 
            6.2.1.2    Global Exosomes Drug Market Forecast Value (2024-2032)
    6.3    Global Exosomes Drug Market by Biomolecule Type
        6.3.1    Market Overview
            6.3.1.1    Non-Coding RNAs
            6.3.1.2    mRNA (exoRNA)
            6.3.1.3    Proteins/Peptides 
            6.3.1.4    DNA Fragments 
            6.3.1.5    Lipids
    6.4    Global Exosomes Drug Market by Product Type
        6.4.1    Market Overview
            6.4.1.1    Kits
            6.4.1.2    Reagents
            6.4.1.3    Instruments
    6.5    Global Exosomes Drug Market by Application 
        6.5.1    Market Overview
            6.5.1.1    Biomarkers
            6.5.1.2    Drug Delivery System
            6.5.1.3    Vaccine Development
            6.5.1.4    Therapeutic Agents
            6.5.1.5    Others
    6.6    Global Exosomes Drug Market by Disease Type
        6.6.1    Market Overview
            6.6.1.1    Cancer Disease
            6.6.1.2    Neurodegenerative Diseases
            6.6.1.3    Cardiovascular Diseases
            6.6.1.4    Infectious Diseases
            6.6.1.5    Tissue Regeneration 
            6.6.1.6    Others
    6.7    Global Exosomes Drug Market by Region
        6.7.1    Market Overview
            6.7.1.1    North America
            6.7.1.2    Europe 
            6.7.1.3    Asia Pacific
            6.7.1.4    Latin America
            6.7.1.5    Middle East and Africa
7    North America  Exosomes Drug Treatment Market
    7.1    Market Share by Country
    7.2    United States of America
        7.2.1    Historical Trend (2017-2023)
        7.2.2    Forecast Trend (2024-2032)
    7.3    Canada
        7.3.1    Historical Trend (2017-2023)
        7.3.2    Forecast Trend (2024-2032)
8    Europe Exosomes Drug Treatment Market
    8.1    Market Share by Country
    8.2    United Kingdom
        8.2.1    Historical Trend (2017-2023)
        8.2.2    Forecast Trend (2024-2032)
    8.3    Germany
        8.3.1    Historical Trend (2017-2023)
        8.3.2    Forecast Trend (2024-2032)
    8.4    France
        8.4.1    Historical Trend (2017-2023)
        8.4.2    Forecast Trend (2024-2032)
    8.5    Italy
        8.5.1    Historical Trend (2017-2023)
        8.5.2    Forecast Trend (2024-2032)
    8.6    Others
9    Asia Pacific Exosomes Drug Treatment Market
    9.1    Market Share by Country
    9.2    China
        9.2.1    Historical Trend (2017-2023)
        9.2.2    Forecast Trend (2024-2032)
    9.3    Japan
        9.3.1    Historical Trend (2017-2023)
        9.3.2    Forecast Trend (2024-2032)
    9.4    India
        9.4.1    Historical Trend (2017-2023)
        9.4.2    Forecast Trend (2024-2032)
    9.5    ASEAN
        9.5.1    Historical Trend (2017-2023)
        9.5.2    Forecast Trend (2024-2032)
    9.6    Australia
        9.6.1    Historical Trend (2017-2023)
        9.6.2    Forecast Trend (2024-2032)
    9.7    Others
10    Latin America Exosomes Drug Treatment Market
    10.1    Market Share by Country
    10.2    Brazil
        10.2.1    Historical Trend (2017-2023)
        10.2.2    Forecast Trend (2024-2032)
    10.3    Argentina
        10.3.1    Historical Trend (2017-2023)
        10.3.2    Forecast Trend (2024-2032)
    10.4    Mexico
        10.4.1    Historical Trend (2017-2023)
        10.4.2    Forecast Trend (2024-2032)
    10.5    Others
11    Middle East and Africa Exosomes Drug Treatment Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
        11.2.1    Historical Trend (2017-2023)
        11.2.2    Forecast Trend (2024-2032)
    11.3    United Arab Emirates
        11.3.1    Historical Trend (2017-2023)
        11.3.2    Forecast Trend (2024-2032)
    11.4    Nigeria
        11.4.1    Historical Trend (2017-2023)
        11.4.2    Forecast Trend (2024-2032)
    11.5    South Africa
        11.5.1    Historical Trend (2017-2023)
        11.5.2    Forecast Trend (2024-2032)
    11.6    Others
12    Current Scenario Evaluation and Regulatory Framework
    12.1    Emerging Therapies and Clinical Trials Synopsis
    12.2    Patent Landscape
        12.2.1    Patent Overview
            12.2.1.1    Patent Status and Expiry
            12.2.1.2    Timelines from Drug Development to Commercial Launch
            12.2.1.3    New Drug Application
                12.2.1.3.1    Documentation and Approval Process
    12.3    Cost of Treatment
    12.4    Investment Scenarios
    12.5    Regulatory Framework
        12.5.1    Regulatory Overview
            12.5.1.1    US FDA
            12.5.1.2    EU EMA
            12.5.1.3    INDIA CDSCO
            12.5.1.4    JAPAN PMDA
            12.5.1.5    Others
13    Challenges and Unmet Need
    13.1    Treatment Pathway Challenges
    13.2    Compliance and Drop-Out Rate
    13.3    Awareness and Prevention Gaps
14    Global Exosomes Drug Market Dynamics
    14.1    Market Drivers and Constraints
    14.2    SWOT Analysis
    14.3    Drug Adoption Parameters
    14.4    Porter’s Five Forces Model
    14.5    Key Demand Indicators
    14.6    Key Price Indicators 
    14.7    Value Chain Analysis
15    Supplier Landscape
    15.1    Danaher Corporation (Beckman Coulter Inc.)
        15.1.1    Company Overview
        15.1.2    Product Portfolio
        15.1.3    Demographic Reach and Achievements
        15.1.4    Mergers and Acquisitions
        15.1.5    Certifications
    15.2    Hologic Inc.
        15.2.1    Company Overview
        15.2.2    Product portfolio
        15.2.3    Demographic Reach and Achievements
        15.2.4    Mergers and Acquisitions
        15.2.5    Certifications
    15.3    Lonza Group AG
        15.3.1    Company Overview
        15.3.2    Product portfolio
        15.3.3    Demographic Reach and Achievements
        15.3.4    Mergers and Acquisitions
        15.3.5    Certifications
    15.4    Fujifilm Holdings Corporation
        15.4.1    Company Overview
        15.4.2    Product portfolio
        15.4.3    Demographic Reach and Achievements
        15.4.4    Mergers and Acquisitions
        15.4.5    Certifications
    15.5    Miltenyi Biotec GmbH
        15.5.1    Company Overview
        15.5.2    Product portfolio
        15.5.3    Demographic Reach and Achievements
        15.5.4    Mergers and Acquisitions
        15.5.5    Certifications
    15.6    Qiagen N.V.
        15.6.1    Company Overview
        15.6.2    Product portfolio
        15.6.3    Demographic Reach and Achievements
        15.6.4    Mergers and Acquisitions
        15.6.5    Certifications
    15.7    Thermo Fisher Scientific Inc.
        15.7.1    Company Overview
        15.7.2    Product portfolio
        15.7.3    Demographic Reach and Achievements
        15.7.4    Mergers and Acquisitions
        15.7.5    Certifications
    15.8    JSR Corporation (MBL International)
        15.8.1    Company Overview
        15.8.2    Product portfolio
        15.8.3    Demographic Reach and Achievements
        15.8.4    Mergers and Acquisitions
        15.8.5    Certifications
    15.9    Illumina, Inc. 
        15.9.1    Company Overview
        15.9.2    Product portfolio
        15.9.3    Demographic Reach and Achievements
        15.9.4    Mergers and Acquisitions
        15.9.5    Certifications
    15.10    Takara Bio Inc.
        15.10.1    Company Overview
        15.10.2    Product portfolio
        15.10.3    Demographic Reach and Achievements
        15.10.4    Mergers and Acquisitions
        15.10.5    Certifications 
    15.11    Malvern Instruments Ltd. (Spectris Plc Company)
        15.11.1    Company Overview
        15.11.2    Product portfolio
        15.11.3    Demographic Reach and Achievements
        15.11.4    Mergers and Acquisitions
        15.11.5    Certifications 
    15.12    Abcam Plc. 
        15.12.1    Company Overview
        15.12.2    Product portfolio
        15.12.3    Demographic Reach and Achievements
        15.12.4    Mergers and Acquisitions
        15.12.5    Certifications
    15.13    Ampersand Capital Partner (New England Peptide, Inc.)
        15.13.1    Company Overview
        15.13.2    Product portfolio
        15.13.3    Demographic Reach and Achievements
        15.13.4    Mergers and Acquisitions
        15.13.5    Certifications 
    15.14    Evox Therapeutics Ltd.
        15.14.1    Company  Overview
        15.14.2    Product portfolio
        15.14.3    Demographic Reach and Achievements
        15.14.4    Mergers and Acquisitions
        15.14.5    Certifications
16    Pricing Models and Strategies (Additional Insight)
    16.1    Cost Model 
        16.1.1    Manufacturing Cost Analysis 
        16.1.2    Procurement Cost Analysis 
    16.2    Pricing Strategies 
        16.2.1    Competitor Pricing Analysis 
        16.2.2    Key Assessment of Product Attributes 
        16.2.3    Pricing Benchmark 
17    Global Exosomes Drug Market- Distribution Model (Additional Insight)
    17.1    Overview
    17.2    Potential Distributors
    17.3    Key Parameters for Distribution Partner Assessment

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The rising prevalence of cancer cases is driving the demand for exosome drugs. The prevalence of cancer cases is likely to grow at the rate of 6.6% during the forecast period of 2024-2032.

The rise in demand for drug therapy in the pharmaceutical and biopharmaceutical field is fuelled by the potential of exosome technology as a diagnostic and therapeutic tool used in the treatment of various diseases, such as neurodegeneration, cardiovascular dysfunction, and cancer.

Based on the product type, the market can be segmented into kits, reagents, and instruments.

Based on the application, the market can be segmented into biomarkers, drug delivery system, vaccine development, therapeutic agents, and others.

Based on the disease type, the market can be fragmented into cancer disease, neurodegenerative disease, cardiovascular disease, infectious disease, tissue regeneration, and others.

The major regions in the industry are North America, Latin America, the Middle East, Africa, Europe, and the Asia Pacific, with North America accounting for the largest share of the market .

North America is expected to dominate the market due to excellent healthcare infrastructure, effective government policies, large base of multinational corporations, and high public awareness about diagnosis and medical assistance.

Danaher Corporation (Beckman Coulter Inc.), Hologic Inc., Lonza Group AG, Fujifilm Holdings Corporation, Miltenyi Biotec GmbH, Qiagen N.V., Thermo Fisher Scientific Inc., JSR Corporation (MBL International), Illumina, Inc., Takara Bio Inc., Malvern Instruments Ltd. (Spectris Plc Company), Abcam Plc., Ampersand Capital Partner (New England Peptide, Inc.), and Evox Therapeutics Ltd. are the top companies in the exosome drug market.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER